Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials.

Christopher L Hallemeier,Peixin Zhang,Thomas M Pisansky,Gerald E Hanks,David G McGowan,Mack Roach,Kenneth L Zeitzer,Selim Y Firat,Siraj M Husain,David P D'Souza,Luis Souhami,Matthew B Parliament,Seth A Rosenthal,Himanshu R Lukka,Marvin Rotman,Eric M Horwitz,Edward F Miles,Rebecca Paulus,Howard M Sandler

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2019）

引用 8|浏览33

暂无评分

摘要

Patients with PSA >0.1 ng/mL after neoAS and before RT start had less favorable clinical outcomes than patients with PSA was ≤0.1 ng/mL. The role of post-neoAS, pre-RT PSA presently, relative to PSA obtained along the continuum of medical care, is not presently defined, but could be tested in future clinical trials.

查看译文

关键词

Prostate cancer,androgen suppression,external beam radiotherapy,prostate specific antigen

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要